Just recently, the University of Minnesota approved a new conflict-of-interest ethics policy for its medical program, which has generated a certain amount of criticism.
Perhaps with that in mind, listen to MPR’s Midmorning program, which discusses the increasingly market-driven nature of pharmaceutical research.
Two bioethicists discuss how such commercialization raises questions about the quality of the data in drug trials, and the safety of the participants in those trials.
One is the University of Minnesota’s own Carl Elliott, professor in the U’s Center for Bioethics. He is the author of “White Coat, Black Hat: Adventures on the Dark Side of Medicine.”
The other is Howard Brody, director of the Institute for the Medical Humanities at the University of Texas Medical Branch.
About the blogger
Alex Friedrich reports on higher education issues for MPR News. Among the stories he has covered: the fall of the Berlin Wall, aftermath of Hurricane Katrina, collapse of the I-35W bridge in Minneapolis, 2003 Moscow suicide bombing and 2004 presidential elections in the Republic of Georgia. He holds a bachelor’s degree in journalism from the University of Georgia and a master’s in European political economy from the London School of Economics.